18F-NOS PET/CT Scan for Parkinson's Disease

Recruiting in Palo Alto (17 mi)

Overseen byJacob Dubroff, MD, PhD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase < 1

Waitlist Available

Sponsor: University of Pennsylvania

No Placebo Group

Approved in 1 Jurisdiction

Trial Summary

What is the purpose of this trial?

The research study is being conducted to test how a specialized type of Positron Emission Tomography (PET/CT) scan could potentially be useful in diagnosing or monitoring treatment in people with Parkinson's disease. If the subject decide to be in this study he/she will have a PET/CT scans using an imaging drug called 18F-NOS which will be used to measure inflammation in the brain.

Research Team

Jacob Dubroff, MD, PhD

Principal Investigator

University of Pennsylvania

Eligibility Criteria

This trial is for people aged 18-75 with Parkinson's disease or healthy individuals interested in brain inflammation research. Participants must understand the study and agree to its procedures. Those with neuropsychiatric disorders can join if it doesn't risk their safety or participation, as judged by an investigator.

Inclusion Criteria

History of diagnosis of probable idiopathic PD derived from UK Brain Bank Diagnostic criteria(1) per neurologist review.

I was diagnosed with Parkinson's Disease over 3 years ago.

Subjects with known neuropsychiatric disorder may be eligible if, in the opinion of an investigator, the psychiatric condition would not compromise subject safety or successful participation in the study.

See 5 more

Treatment Details

Interventions

[18F]NOS (Imaging Agent)

Trial OverviewThe study tests a PET/CT scan using a tracer called 18F-NOS to detect brain inflammation, which could help diagnose or monitor Parkinson's disease treatment effectiveness.

Participant Groups

2Treatment groups

Experimental Treatment

Group I: Patient with Parkinson DiseaseExperimental Treatment1 Intervention

Subject should have a history of diagnosis of probable idiopathic PD derived from UK Brain Bank Diagnostic criteria per neurologist review. Subject must have been diagnosed with Parkinson's Disease at least 3 year prior to enrollment.

Group II: Healthy ControlExperimental Treatment1 Intervention

Subject must be a Healthy.